Compare · AVGR vs RMD
AVGR vs RMD
Side-by-side comparison of Avinger Inc. (AVGR) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVGR and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $27.05B, about 1000.8x AVGR ($27.0M).
- RMD has hit the wire 7 times in the past 4 weeks while AVGR has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 2 for AVGR).
- Company
- Avinger Inc.
- ResMed Inc.
- Price
- $0.47-23.45%
- $186.48+1.93%
- Market cap
- $27.0M
- $27.05B
- 1M return
- -
- -10.85%
- 1Y return
- -
- -25.39%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 0
- 7
- Recent ratings
- 2
- 25
Avinger Inc.
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest AVGR
- Amendment: SEC Form SCHEDULE 13G/A filed by Avinger Inc.
- Avinger Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Changes in Registrant's Certifying Accountant, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Avinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Vice President, Finance Subainati Nabeel Paul sold $699 worth of shares (1,255 units at $0.56), decreasing direct ownership by 28% to 3,296 units (SEC Form 4)
- Chief Executive Officer Soinski Jeffrey M sold $2,054 worth of shares (3,690 units at $0.56), decreasing direct ownership by 6% to 55,265 units (SEC Form 4)
- Chief Technology Officer Patel Himanshu sold $1,233 worth of shares (2,215 units at $0.56), decreasing direct ownership by 5% to 39,062 units (SEC Form 4)
- SEC Form DEFA14A filed by Avinger Inc.
- Avinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 144 filed by Avinger Inc.
- Avinger Inc. filed SEC Form 8-K: Other Events
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.